Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs Post ContentxeneRead More You might also be interested in reading What have the US and EU agreed on trade?. August 12, 2025 In Mainstream ← Previous post Next post →